Please ensure Javascript is enabled for purposes of website accessibility

Why Axsome Therapeutics Stock Is Jumping Today

By Keith Speights - Apr 26, 2021 at 12:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA granted Priority Review to the biotech's regulatory filing for its lead pipeline candidate.

What happened

Shares of Axsome Therapeutics (AXSM 6.11%) were jumping 8.4% as of 11:41 a.m. EDT on Monday after rising as much as 16.3% earlier in the day. The nice gain came following the company's announcement that the Food and Drug Administration accepted the New Drug Application (NDA) filing for AXS-05 in treating major depressive disorder. As an added bonus, the FDA granted Priority Review to the regulatory application.

So what

Investors cheered today's news because it means that Axsome jumped a key hurdle in its path to winning FDA approval for AXS-05. The FDA's granting of Priority Review makes the finish line even closer. This designation reduces the agency's review time from 10 months to six months after acceptance of the NDA filing.

Man wearing a coat and tie holding yellow blocks spelling FDA in his hand

Image source: Getty Images.

Axsome should have a big market opportunity if AXS-05 wins FDA approval. Around 17 million adults in the U.S. are affected by major depressive disorder. At least one-third have treatment-resistant depression. 

The company's chances of obtaining FDA approval for AXS-05 appear to be pretty good. Axsome previously reported results from two late-stage clinical studies that showed the drug achieved statistically significant improvements in symptoms of depression compared to placebo and active controls.

Now what

FDA approval of AXS-05 would be a major catalyst for the biotech stock, but investors will have to wait a few months -- the FDA's decision is expected by Aug. 22. In the meantime, Axsome plans to submit an NDA in the near future for another candidate, AXS-07, for treating migraine.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Axsome Therapeutics, Inc. Stock Quote
Axsome Therapeutics, Inc.
$40.64 (6.11%) $2.34

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.